Drug Profile
NSR AAV-MD
Alternative Names: AAV-MDLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator NightstaRx
- Developer Biogen
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Macular degeneration
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Macular-degeneration in United Kingdom (Intraocular)
- 23 Mar 2017 Preclinical trials in Macular degeneration in United Kingdom (Intraocular)
- 23 Mar 2017 NightstaRx plans a phase I/II trial for Macular degeneration in late 2018 (NightstaRx website, March 2017)